BIO2013 Fellowship Winner – Eliza Whiteside

Every year, IHBI, bluebox and QUT’s Division of Research and Commercialisation sponsor three early- to mid-career researchers to attend the Biotechnology Industry Organisation (BIO) conference in the USA. This year, Dr Melissa Fernandez, Dr Roland Steck and Dr Eliza Whiteside have been selected as the 2013 BIO Fellows. Today we will meet Dr Eliza Whiteside.

Dr Eliza Whiteside is a Queensland UniverEliza Whitesidesity of Technology (QUT) lecturer in biotechnology and an early career researcher at the Institute of Health and Biomedical Innovation in the field of medical biotechnology.  Although trained as a basic scientist with a strong molecular and cell biology skill set, Eliza’s current research interests and growing expertise is in the area of translatable, patient-focused research.  Eliza’s own personal battle with breast cancer and her volunteer role with the National Breast Cancer Foundation in Australia have inspired her to investigate novel genetic and proteomic biomarkers as indicators of breast cancer risk and recurrence, as well as ‘wellness’ in breast cancer sufferers.  Eliza and her research group are primarily focused on the role of glycoprotein hormones and their receptors and employ loss of function and over-expression models using cell and molecular-based technologies to investigate tumourigenesis and cancer progression. Her group’s research is also investigating the use of novel and established pharmaceuticals, nutraceuticals, physical activity and sleep to ameliorate the side effects of common breast cancer treatments.

http://www.linkedin.com/pub/eliza-whiteside/11/756/862

BIO is the largest biotechnology conference in the world, with approximately 16,500 attendees expected to attend this year’s event in Chicago. Along with a feature-packed conference program, BIO also offers a one-on-one BIO Business Forum and an exhibition hall with over 1,600 companies showcasing their latest products and technologies. BIO covers the complete spectrum of life sciences areas and biotechnology applications. From drug discovery to biomanufacturing, genomics to biofuels, cell therapy to nanotechnology – BIO has it covered.

BIO2013 Fellowship Winner – Roland Steck

Every year, IHBI, bluebox and QUT’s Division of Research and Commercialisation sponsor three early- to mid-career researchers to attend the Biotechnology Industry Organisation (BIO) conference in the USA. This year, Dr Melissa Fernandez, Dr Roland Steck and Dr Eliza Whiteside have been selected as thRoland Stecke 2013 BIO Fellows. Today we will meet Dr Roland Steck.

Dr Steck is the Deputy Director of the Medical Engineering Research Facility (MERF) at QUT, and a Senior Research Fellow in the Trauma Research Group at QUT’s Institute of Health and Biomedical Innovation (IHBI). Roland joined QUT in 2005 to establish the research program for the Chair of Trauma, Prof. M. Schuetz. This research group now conducts experimental research and develops computational simulation methods to study and improve bone fracture and defect healing. Roland’s own research interests include the development and characterisation of novel fracture fixation implants for murine models of diaphyseal and metaphyseal bone fracture healing, as well as new experimental models of soft tissue trauma. For this and other related research he has established advanced evaluation protocols mechanical testing and microCT. In 2011, he was appointed as Deputy Director of MERF, a state-of-the-art research and teaching facility with surgical theatres for pre-clinical studies, research laboratories and surgical skills laboratories. In this role, Roland works on developing MERF into a technology rich interface between the health community and industry by providing a research and training environment that facilitates the translation of novel concepts from basic research to clinical implementation.

http://www.linkedin.com/pub/roland-steck/9/994/227

BIO is the largest biotechnology conference in the world, with approximately 16,500 attendees expected to attend this year’s event in Chicago. Along with a feature-packed conference program, BIO also offers a one-on-one BIO Business Forum and an exhibition hall with over 1,600 companies showcasing their latest products and technologies. BIO covers the complete spectrum of life sciences areas and biotechnology applications. From drug discovery to biomanufacturing, genomics to biofuels, cell therapy to nanotechnology – BIO has it covered.

BIO2013 Fellowship Winner – Melissa Fernandez

Every year, IHBI, bluebox and QUT’s Division of Research and Commercialisation sponsor three early- to mid-career researchers to attend the Biotechnology Industry Organisation (BIO) conference in the USA. This year, Dr Melissa Fernandez, Dr Roland Steck and Dr Eliza Whiteside have been selected as the 2013 BIO Fellows. Today we will meet Dr Melissa Fernandez.

Dr MMelissa Fernandezelissa Fernandez is an early career researcher within the Wound Management Innovation Cooperative Research Centre (CRC). Her research interests are in biochemistry, proteomics, metabolomics as well as wound healing. Dr Fernandez’s postgraduate training focused on using a proteomic and metabolomic approach to identify prognostic and diagnostic indicators of wound healing. During this time, she received a Queensland Smart State PhD scholarship to support her work. Currently, Melissa is a postdoctoral researcher focusing on the development and of novel treatments for patients suffering from chronic, non-healing wounds. During this work, she has discovered that uric acid is elevated in wound fluid from patients with chronic venous leg ulcers and correlates with wound severity. Using this knowledge, Melissa has developed a novel wound therapy, which is about to be trialed in patients, using the topical application of allopurinol, a cheap, off patent and registered drug product. If successful, this topical treatment with allopurinol will prevent sustained inflammation and stimulate wound repair, thus reducing the duration of compression therapy.

BIO is the largest biotechnology conference in the world, with approximately 16,500 attendees expected to attend this year’s event in Chicago. Along with a feature-packed conference program, BIO also offers a one-on-one BIO Business Forum and an exhibition hall with over 1,600 companies showcasing their latest products and technologies. BIO covers the complete spectrum of life sciences areas and biotechnology applications. From drug discovery to biomanufacturing, genomics to biofuels, cell therapy to nanotechnology – BIO has it covered.

 

Enabling women to manage their own wellbeing – The Women’s Wellness Program

Last year bluebox invested Proof-of-Concept (POC) funding in over 10 successful POC applications. The projects range from getting a consultant on board for a short period of time to provide commercial feasibility assessment, collecting data to compare the innovation to current gold standard in industry, and the development and trialing of prototypes.

Professor Debra Anderson was one of the successful applicants that received investment to package and develop an online delivery system for the Women’s Wellness Program. Evidence-based, the piStock_000006244050Largerogram is targeted at midlife women, providing them with tools to manage their own health and wellbeing through a supportive 12-week program, which targets decreasing menopausal symptoms and reducing chronic disease risk factors.

This research builds on the demonstrated success of the existing Women’s Wellness program, which is an intensive consultation and paper-based intervention. The POC investment from bluebox will assist Professor Anderson and her team to update the women’s wellness program paper based materials and produce an e-book/journal, develop an interactive online delivery system to support the program, pilot e-health consultation support and update training materials for health professionals to deliver the program. Three approaches will be trial in a pilot study of the system. The program is aimed at enabling busy women to manage their own wellbeing, whilst on the move!

I am constantly bombarded with information that often contradicts itself. As a busy women myself, I welcome reputable evidence based information that is supportive and accessible whilst I’m on the move. One recent example is becoming a new mother, wow, what an information overload in getting ready for a new life to enter our home. Then once the baby arrives, you completely forget or ignore everything you have read and rely on family and friends for just as contradictory advice… I can say the tools that I did end up using were on my smartphone, applications and websites that were developed based on evidence, helping me understand why I all of a sudden have a screaming child for hours on end.

The POC project is currently underway, the paper materials have been updated and currently developing the interactive online system. Phase 1 of the online system where potential participants can register their interest is now LIVE! In a couple of months time Phase 2, the launch of the program, will occur and the trial will begin – watch this space!

If you want to learn more please visit the website and register your interest to be part of the trial at www.womenswellness.com.au

Otherwise you can always contact me, Lisa van den Berg – Commercialisation Manager at qutbluebox 

What is POC funding?

The bluebox Proof-of-Concept (POC) Fund has been established to enable the development of intellectual property to “proof of concept” and to enhance the ability to achieve QUT’s commercial goal of reinforcing its applied emphasis and securing significant commercial and practical outcomes –social, community or commercial. The success indicator for each investment will be specific, targeted application to measurable commercial milestones. The fund does not operate as a general research support grant.